Lastly, miR-185 and miR-342 have been shown to control lipogenesis and cholesterogenesis by inhibiting SREBP-1 and -2 expression and downregulating their target genes (FASN and HMG-CoA reductase) in prostate cancer [105]. This evidence concerns the gene SREBF1 and Familial prostate cancer.